More Recce Pharmaceuticals Ltd. news
Recce Pharmaceuticals Ltd.ASX: RCE

Appendix 4C and commentary

Jul 30, 2019 at 12:19 AM EDT · Issued by Recce Pharmaceuticals Ltd.

Filed with ASX · Jul 30, 2019 at 12:19 AM EDT

On 6ix: 6ix.com/news/appendix-4c-and-commentary-1

Recce Ltd has released a press release.

View Attachment

6ix hasn’t read this filing yet.

Recce Pharmaceuticals Ltd. on 6ix

Earlier from Recce Pharmaceuticals

  • Appointment of Independent Chair and Additional DirectorJul 9, 2019
  • USA Patent Granted for Recces AntibioticsMar 13, 2019
  • Recce Successfully Raises $1.8 million via PlacementFeb 7, 2019
  • Change of Registry Address: Automic P/L - Sydney OfficeSep 28, 2018
  • Key Australian Patent for Recces Broad-Spectrum AntibioticsJul 31, 2018

Later from Recce Pharmaceuticals

  • Opening R&D Address at World Antibiotic Resistance CongressJul 31, 2019
  • Key Family 2 Patent Granted in Europe for RECCE AntibioticsAug 8, 2019
  • Response to ASX Appendix 4C QueryAug 16, 2019
  • FDA Positive Response for Recce Scaled Manufacture & QualityAug 26, 2019
  • Appendix 4E - Preliminary Final ReportAug 30, 2019
All Recce Pharmaceuticals news releases↗

Follow Recce Pharmaceuticals into a list and get an email when it puts out news.

Follow Recce Pharmaceuticals
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer